Catatan sumber primer
PenentuPerubahan registri uji klinis
RP-A501 · NCT06092034 registry update
primary_completion: 2028-04 → 2028-06; completion: 2032-04 → 2032-06; enrollment: 14 → 18; primary_outcomes: ['Evaluation of efficacy via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index'] → ['Evaluation of Efficacy: Improvement as assessed via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index (LVMI)']
Fakta utama
- Diajukan
- 6 Okt 2026, 15.21
- Peristiwa
- Perubahan registri uji klinis
- Arah
- Netral
- Perusahaan
RCKTRocket Pharmaceuticals- Aset
- RP-A501
- Sumber
- ClinicalTrials.gov
- Keyakinan
- Bersumber
- pivotal N
- 12
- phase1 lvm
- 5/6 below baseline at 3-7y
- lvm reduction
- ≥10%
- lamp2 expression
- ≥Grade 1
- original dose lvm
- 3/4 achieved ≥10% reduction
- success threshold
- at least 7/12 patients meeting both co-primary endpoints
Selengkapnya tentang aset ini
6 Okt 2026
21.15
RCKTRocket Pharmaceuticals15 Sep 2026
11.06
RCKTRocket Pharmaceuticals